Vital epidemiologic clues in heart failure

Journal of Clinical Epidemiology

Volumn 53, Issue 3, 2000, Pages 229-235

  Kannel, W B ^a  

^a FRAMINGHAM HEART STUDY   (United States)

Author keywords

Epidemiology; Heart failure; Hypertension; Predisposing conditions

Indexed keywords

ANGINA PECTORIS; ARTICLE; CARDIOMEGALY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; EPIDEMIOLOGY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; CAUSALITY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 0034020705     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(99)00135-3     Document Type: Article

References (37)

1. Data fact sheet. Congestive Heart Failure in the United States: A New Epidemic:1996;NHLBI Information Center, Bethesda, MD.
2. Schocken D.D., Arrieta M.I., Leaverton P.E., Ross E.A. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 20:1992;301-306.
3. Ho K.K.L., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure. The Framingham Study J Am Coll Cardiol. 22A6a-13a:1993.
4. Kannel W.B., Thom T.J. Incidence prevalence and mortality of cardiovascular diseases. Schlant R.C. The Heart. 8th ed:1994;McGraw-Hill, New York.
5. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on morbidity and mortality in patients with heart failure. Collaborative Group on ACE-Inhibitor Trials JAMA. 273:1995;1450-1456.
6. Changes in mortality from heart failure - United States, 1980-1995. Morbid Mortal Weekly Rep 1998;47(30):633-7.
7. Andrews R., Cowley A.J. Clinical and economic factors in the treatment of congestive heart failure. Pharmacoeconomics. 7(2):1995;119-127.
8. American Heart Association. 1997 Heart and Stroke: Statistical Update. Dallas, TX.
9. Graves E.G., Gillum B.S. 1994 Summary. National Hospital Discharge Survey: Advance Data National Center for Health Statistics. 278:1996;1-12.
10. Ranofsky A. Inpatient utilization of short stay hospitalization by diagnosis. United States. 1971. National Center for Health Statistics. DHEW Pub No. (HRA) 75-1767; 1974.
11. Brown A.M., Cleland J.G.F. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 19:1998;1063-1069.
12. McMurray J., McDonough T., Morrison C.E., Dargie H.J. Trends for hospitalization for heart failure in Scotland. 1980-1990. Eur Heart J. 14:1993;1158-1162.
13. Cleland J.G.F., Erdmann E., Ferrari R. Guidelines for the diagnosis of heart failure. Eur Heart J. 16:1995;741-751.
14. National Heart Lung and Blood Institute. Morbidity and Mortality Chartbook on Cardiovascular, Lung and Blood Disease. NIH, Bethesda, MD; 1996.
15. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
16. Gandhi M.M. Clinical epidemiology of coronary heart disease in the UK. Br J Hospital Med. 58:1997;23-27.
17. Effect of enalapril on mortality in severe congestive heart failure. Results of the co-operative North Scandinavian Enalapril Survival Study. New Engl J Med. 316:1987;1429-1435.
18. Effect of Rampiril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;8321-8328.
19. Konstam M.A., Kronenberg M.W., Rousseau M.F., Udelson J.E., Melin J., Stewart D.et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation. 88(5):1993;2277-2283.
20. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325(5):1991;293-302.
21. Brophy T.M. Epidemiology of congestive heart failure. Canadian data from 1970 to 1989 Can J Cardiol. 8(5):1992;495-498.
22. Levy D., Larson M.G., Vasan R.S., Kannel W.B., Ho K.K.L. The progression from hypertension to congestive heart failure. JAMA. 275:1996;1557-1562.
23. National High Blood Pressure Education Working Group on primary prevention of hypertension. Arch Intern Med. 153:1993;186-208.
24. Lackland D.T., Kiel J.E. Epidemiology of hypertension in African Americans. Semin Nephrol. 16:1996;63-70.
25. Kannel W.B., Ho K., Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 72:1994;S3-S9.
26. Kannel W.B. Need and prospects for prevention of cardiac failure. Eur J Clin Pharmacol. 49:1996;S3-S9.
27. Kannel W.B., Wilson P.W.F. Comparison of risk profiles for cardiovascular events. implications for prevention Adv Intern Med. 42:1997;39-66.
28. Gillum R.F. Idiopathic cardiomyopathy on the United States, 1970-1982. Am Heart J. 11:1986;752-755.
29. Sugrue D.D., Rodeheffer R.J., Codd M.B., Ballard D.J., Fuster V., Gersh B.J. The clinical course of idiopathic dilated cardiomyopathy. A population based study. Ann Intern Med. 117(2):1992;117-123.
30. Rakar S., Sinagra A., Di Lenarda A., Poletti A., Bussani R., Silvestri F., Cameri F., the Heart Muscle Disease Group Epidemiology of dilated cardiomyopathy. A postmortem study of 5252 necropsies. Eur Heart J. 18:1997;117-123.
31. Kannel W.B., Belanger A.J. Epidemiology of heart failure. Am Heart J. 121:1991;951-957.
32. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1990;1561-1566.
33. US Department of Health and Human Services. National Heart Lung and Blood Institute. Report of the Task Force on Research on Heart Failure; 1994.
34. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. the Scandinavian Simvastatin Survival Study (4S) Lancet. 344:1994;1380-1389.
35. Furberg C.D., Yusuf S. Effect of drug therapy on survival in chronic heart failure. Adv Cardiol. 34:1986;124-130.
36. Cutler J.A., Psaty B.M., McMahon S., Furberg C.D. Public health issues in hypertension control. what has been learned from clinical trials Laragh J.H., Brenner B.H. Hypertension. Pathophysiology, Diagnosis and Management:1995;253-270 Raven Press Ltd, New York.
37. Heidenreich P.A., Lee T.T., Massie B.M. Effect of beta-blockade on mortality in patients with heart failure; a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 30:1997;27-34.